some positive coverage from the us, page-15

As per squelch's link and then clicking "Unilife jumps on analyst view of unifill sales" (I didn't post the link as it was too long), I really like these comments:

"The company is in the development stage now, but Denhoy said he thinks commercialization of Unifill products could start in 2013, approach $500 million in annual sales in fiscal 2016, and reach $670 million in fiscal 2017."

"Unilife is developing a Unifill version of the company's injectable blood thinner Lovenox (WOW, this and the above and below comments may be why the SP is moving IMO)."

"Denhoy said he thinks the York, Pa., company will strike around 30 license and development deals, and he expects about half of those products to reach the market."

I don't think I have seen anything about both unifill and Lovenox mentioned before in media. If this is in fact Raj Denhoy stating this, he seems very confident about it. I may be wrong but would like to get others opinions on this.